These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 31346157)
1. A pharmacogenetic intervention for the improvement of the safety profile of antipsychotic treatments. Arranz MJ; Gonzalez-Rodriguez A; Perez-Blanco J; Penadés R; Gutierrez B; Ibañez L; Arias B; Brunet M; Cervilla J; Salazar J; Catalan R Transl Psychiatry; 2019 Jul; 9(1):177. PubMed ID: 31346157 [TBL] [Abstract][Full Text] [Related]
2. Genetic testing for CYP2D6 and CYP2C19 suggests improved outcome for antidepressant and antipsychotic medication. Walden LM; Brandl EJ; Tiwari AK; Cheema S; Freeman N; Braganza N; Kennedy JL; Müller DJ Psychiatry Res; 2019 Sep; 279():111-115. PubMed ID: 29699889 [TBL] [Abstract][Full Text] [Related]
3. High levels of several antipsychotics and antidepressants due to a pharmacogenetic cause: a case report. Mian P; Somers M; Berg MT; Cahn W; Wilting I; Schaik RV Pharmacogenomics; 2019 Jun; 20(8):567-570. PubMed ID: 31190622 [TBL] [Abstract][Full Text] [Related]
4. Genetic Determinants of Clozapine-Induced Metabolic Side Effects. Vasudev K; Choi YH; Norman R; Kim RB; Schwarz UI Can J Psychiatry; 2017 Feb; 62(2):138-149. PubMed ID: 27681143 [TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics and antipsychotics in the light of personalized pharmacotherapy. Mihaljević-Peles A; Sagud M; Bozina N; Zivković M; Jovanović N Psychiatr Danub; 2010 Jun; 22(2):335-7. PubMed ID: 20562776 [TBL] [Abstract][Full Text] [Related]
6. Impact of CYP1A2, CYP2C19, and CYP2D6 genotype- and phenoconversion-predicted enzyme activity on clozapine exposure and symptom severity. Lesche D; Mostafa S; Everall I; Pantelis C; Bousman CA Pharmacogenomics J; 2020 Apr; 20(2):192-201. PubMed ID: 31616047 [TBL] [Abstract][Full Text] [Related]
7. Alcohol intake potentiates clozapine adverse effects associated to CYP1A2*1C in patients with refractory psychosis. Ortega-Vázquez A; Mayen-Lobo YG; Dávila-Ortiz de Montellano DJ; Tristán-López L; Aviña-Cervantes CL; Ríos C; López-López M; Monroy-Jaramillo N Drug Dev Res; 2021 Aug; 82(5):685-694. PubMed ID: 33336447 [TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450 genotypes are not associated with refractoriness to antipsychotic treatment. van de Bilt MT; Prado CM; Ojopi EP; Sousa RT; Loch AA; Zanetti MV; Talib LL; Gattaz WF Schizophr Res; 2015 Oct; 168(1-2):587-8. PubMed ID: 26298540 [TBL] [Abstract][Full Text] [Related]
9. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Dahl ML Clin Pharmacokinet; 2002; 41(7):453-70. PubMed ID: 12083975 [TBL] [Abstract][Full Text] [Related]
10. Effect of Routine Cytochrome P450 2D6 and 2C19 Genotyping on Antipsychotic Drug Persistence in Patients With Schizophrenia: A Randomized Clinical Trial. Jürgens G; Andersen SE; Rasmussen HB; Werge T; Jensen HD; Kaas-Hansen BS; Nordentoft M JAMA Netw Open; 2020 Dec; 3(12):e2027909. PubMed ID: 33284338 [TBL] [Abstract][Full Text] [Related]
11. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool. de Leon J; Susce MT; Murray-Carmichael E Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600 [TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Arranz MJ; de Leon J Mol Psychiatry; 2007 Aug; 12(8):707-47. PubMed ID: 17549063 [TBL] [Abstract][Full Text] [Related]
13. CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects. Ivanova SA; Filipenko ML; Vyalova NM; Voronina EN; Pozhidaev IV; Osmanova DZ; Ivanov MV; Fedorenko OY; Semke AV; Bokhan NA Bull Exp Biol Med; 2016 Mar; 160(5):687-90. PubMed ID: 27021090 [TBL] [Abstract][Full Text] [Related]
14. The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes. Zivković M; Mihaljević-Peles A; Sagud M; Silić A; Mihanović M Psychiatr Danub; 2010 Mar; 22(1):112-6. PubMed ID: 20305604 [TBL] [Abstract][Full Text] [Related]
15. The Influence of CYP2D6 and CYP2C19 Genetic Variation on Diabetes Mellitus Risk in People Taking Antidepressants and Antipsychotics. Austin-Zimmerman I; Wronska M; Wang B; Irizar H; Thygesen JH; Bhat A; Denaxas S; Fatemifar G; Finan C; Harju-Seppänen J; Giannakopoulou O; Kuchenbaecker K; Zartaloudi E; McQuillin A; Bramon E Genes (Basel); 2021 Nov; 12(11):. PubMed ID: 34828364 [TBL] [Abstract][Full Text] [Related]
16. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment. Plesnicar BK; Zalar B; Breskvar K; Dolzan V J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753 [TBL] [Abstract][Full Text] [Related]
18. Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients. Melkersson KI; Scordo MG; Gunes A; Dahl ML J Clin Psychiatry; 2007 May; 68(5):697-704. PubMed ID: 17503978 [TBL] [Abstract][Full Text] [Related]
19. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. Murray M J Pharm Pharmacol; 2006 Jul; 58(7):871-85. PubMed ID: 16805946 [TBL] [Abstract][Full Text] [Related]